RYR2 (Ryanodine Receptor 2)

The model is robust and effectively reflects NSCLC heterogeneity while predicting prognosis. RORA promotes the expression of ZNF490 to inhibit NUDFs and oxidative phosphorylation.

FBXO45 is a key E3 ubiquitin ligase in ovarian cancer, promoting growth, spread and migration via the Wnt/β-catenin pathway. Ubiquitination-related markers provide reliable prognostic insights and reflect the immune microenvironment in ovarian cancer, offering a basis for clinical targeting strategies.

The results of this study endorse the possibility of performing a genetic screening before anticancer immunochemotherapy as a future tool for stratifying patients with an oncohematological profile and minimizing CV toxicity. However, further studies are needed to confirm the diagnostic and prognostic role of the above identified genetic variants.

P2, N=7, Terminated, Cardurion Pharmaceuticals, Inc. | N=12 --> 7 | Trial completion date: Sep 2025 --> May 2025 | Recruiting --> Terminated; The early termination of the clinical trial is due to an internal administrative and business decision, the study is not being terminated for safety reasons.

Knockdown of RYR2 in LUAD cells inhibited the production of chemokines, particularly CCL14 and CXCL12. In conclusion, our study reveals that RYR2 functions as a tumor suppressor in LUAD by inducing mitochondrial dysfunction and promoting immune cell infiltration.

Short-term concomitant use of dantrolene offers a promising and clinically feasible strategy to prevent DIC. Given dantrolene's established clinical safety as a treatment for malignant hyperthermia, these findings suggest potential for repositioning dantrolene in DIC prevention.

P2, N=12, Recruiting, Cardurion Pharmaceuticals, Inc. | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Nov 2024 --> Jul 2025

The results of our study, in which RYR2 SNPs associated with OSCC progression and development were examined for the first time, suggest that clinicopathological characteristics may alter OSCC susceptibility. Finally, RYR2 SNP rs2779359 not only plays a role in both the prognosis and diagnosis of oral cancer but is also likely an important predictive factor for recurrence, response to treatment, and medication toxicity.

This is the first study to show that specific KRAS and RYR2 mutations were associated with the URFS.

P2, N=12, Recruiting, Cardurion Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting | Phase classification: P2a --> P2

Pure NEC has different somatic mutation profile than other NECs. This study provides insights into the mechanism of tumorigenesis in G-NEC.